EyePoint Pharmaceuticals Inc. (EYPT)
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears
Eyepoint Pharmaceuticals NASDAQ: EYPT executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint, Inc. (EYPT) Q1 2026 Earnings Call Transcript
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $0.65 per share a year ago.
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating on the
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago.
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know
Does EyePoint (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
